Hikma has a total of 142 patents globally, out of which 92 have been granted. Of these 142 patents, more than 78% patents are active. The United States of America is where Hikma has filed the maximum number of patents, followed by China and Europe. Parallelly, the United States of America seems to be the main focused R&D centre and also the United Kingdom is the origin country of Hikma.
Hikma was founded in 1978. Hikma creates, produces, and sells pharmaceutical goods. The business sells pharmaceutical items that are in-licensed, generic, and branded. As of February 2023, Hikma Pharmaceuticals has a market cap of $4.61 Billion.
Do read about some of the most popular patents of Hikma which have been covered by us in this article and also you can find Hikma patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Hikma patent portfolio.
How many patents do the Founder and CEO of Hikma have?
The Founder Samih Darwazah have 0 patents and CEO Said Darwazah have 0 patents.
How many patents does Hikma have?
Hikma has a total of 142 patents globally. These patents belong to 57 unique patent families. Out of 142 patents, 112 patents are active.
How Many Patents did Hikma File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Hikma Applications Filed | Hikma Patents Granted |
| 2023 | – | 1 |
| 2022 | 2 | 5 |
| 2021 | 8 | 7 |
| 2020 | 2 | 18 |
| 2019 | 27 | 5 |
| 2018 | 11 | 4 |
| 2017 | 9 | 6 |
| 2016 | 6 | 1 |
| 2015 | 2 | 4 |
| 2014 | 10 | 2 |
| 2013 | 5 | 4 |
| 2012 | 1 | 1 |
| 2011 | 14 | 18 |
Explore the top-performing drugs that dominate the Pharmaceutical Industry
| Patent Number | Company | Product | Brand | Revenue | Patent Expiry Date |
| US9174975 | Sumitomo Pharma | Lurasidone Hydrochloride | Latuda | $1.75B | Jun-26 |
| US7612199 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US7902206 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US8158644 | Alfasigma | Rifaximin | Xifaxan | $1.64B | Nov-24 |
| US7371727 | Ironwood Pharma | Linaclotide | Linzess | $1.00B | Mar-25 |
Want to know which drugs are making over $1 Billion annually?
How many Hikma patents are Alive/Dead?
How Many Patents did Hikma File in Different Countries?
Countries in which Hikma Filed Patents
| Country | Patent |
| United States Of America | 97 |
| China | 20 |
| Europe | 6 |
| Japan | 5 |
| Canada | 3 |
| Australia | 1 |
| Mexico | 1 |
| Jordan | 1 |
| Saudi Arabia | 1 |
| United Kingdom | 1 |
| Hong Kong (S.A.R.) | 1 |
Where are Research Centers of Hikma Patents Located?
10 Best Hikma Patents
US20030118641A1 is the most popular patent in the Hikma portfolio. It has received 338 citations so far from companies like Grünenthal, Labopharm, Penwest Pharmaceuticals.
Below is the list of 10 most cited patents of Hikma:
| Publication Number | Citation Count |
| US20030118641A1 | 338 |
| US20050163856A1 | 226 |
| US7918830B2 | 87 |
| USD593613S1 | 82 |
| USD588200S1 | 71 |
| USD649196S1 | 60 |
| USD597608S1 | 59 |
| USD645094S1 | 53 |
| USD639863S1 | 53 |
| USD621879S1 | 53 |
What Percentage of Hikma US Patent Applications were Granted?
Hikma (Excluding its subsidiaries) has filed 19 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 19 have been granted leading to a grant rate of 100%.
Below are the key stats of Hikma patent prosecution at the USPTO.
Which Law Firms Filed Most US Patents for Hikma?
| Law Firm | Total Applications | Success Rate |
| Hamilton Brook Smith & Reynolds | 11 | 100% |
| Pearne & Gordon | 8 | 100% |